Biotechnology and Pharmaceuticals

April 26, 2013

Topics covered: Orphan Drug and Biologics Manufacturing, Health Care, Executive Officer Interviews, Biotechnology and Pharmaceuticals, Biotechnology and Pharmaceutical Investing, Biotechnology and Pharmaceutical Companies Valuation

Companies covered: Celgene Corporation (NASDAQ:CELG), Biogen Idec Inc. (NASDAQ:BIIB), Amgen Inc. (NASDAQ:AMGN), Seattle Genetics, Inc. (NASDAQ:SGEN), Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN), Pharmacyclics, Inc. (NASDAQ:PCYC), Merck & Company, Inc. (NYSE:MRK), The Medicines Company (NASDAQ:MDCO), Johnson & Johnson (NYSE:JNJ), Infinity Pharmaceuticals, Inc. (NASDAQ:INFI), ImmunoGen, Inc. (NASDAQ:IMGN), Gilead Sciences, Inc. (NASDAQ:GILD), Cubist Pharmaceuticals Inc., Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN), Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN), Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), Theravance, Inc. (NASDAQ:THRX), Optimer Pharmaceuticals, Inc., Eli Lilly and Company (NYSE:LLY), InterMune Inc., Idenix Pharmaceuticals Inc., GlaxoSmithKline PLC (NYSE:GSK), ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA), YM BioSciences Inc., Life Technologies Corporation, Illumina, Inc. (NASDAQ:ILMN), Bristol-Myers Squibb Company (NYSE:BMY), Abbott Laboratories (NYSE:ABT), Celldex Therapeutics, Inc. (NASDAQ:CLDX), Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), Pluristem Therapeutics, Inc. (NASDAQ:PSTI), Aastrom Biosciences, Inc., NovaBay Pharmaceuticals, Inc. (AMEX:NBY), Akorn, Inc. (NASDAQ:AKRX), Valeant Pharmaceuticals International, Inc. (NYSE:VRX), Teva Pharmaceutical Industries Limited (NYSE:TEVA), Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP), Mylan Inc. (NASDAQ:MYL), Jazz Pharmaceuticals plc (NASDAQ:JAZZ), Forest Laboratories Inc., Endo International plc (NASDAQ:ENDP), Allergan, Inc. (NYSE:AGN), Neurocrine Biosciences, Inc. (NASDAQ:NBIX), Incyte Corporation (NASDAQ:INCY), Astrazeneca PLC (NYSE:AZN)

Buy ($175)

Pin It on Pinterest

Share This